WARSAW, Ind., Oct. 19, 2023 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics”) (NASDAQ: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, announced today it has released the new Pediatric Nailing Platform TIBIA system and successfully completed the first cases in its limited launch. The Company received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the system in September 2023.
Part of the Trauma & Deformity Correction suite of products, PNP Tibia represents another pediatric-focused solution for treating patients with fractures and deformities in the lower extremities. It expands the Company’s offering to 52 unique systems designed specifically to help treat the needs of pediatric patients. The PNP Tibia System features rigid cannulated nails, ranging in diameters from 7mm-12mm, and includes specialized instrumentation to facilitate multiple surgical techniques. Like other OrthoPediatrics products, this system was designed for children’s anatomy and growing patients.
The PNP Tibia system’s versatility and scope was on full display for these two surgical cases. One case was a trauma procedure for a 6’5” teenager who required a large nail (12mm X 420mm), while the other was a deformity correction procedure for a smaller stature 15-year-old where a 7mm X 285mm nail was used. These two cases reflect OP having the broadest scope of pediatric focused cannulated nails in the industry allowing surgeons to address kids of all sizes and needs.
Joe Hauser, President of OrthoPediatrics’ Trauma & Deformity Correction business stated, “It is extremely gratifying to see the system perform successfully in two unique and challenging cases. It shows the expert surgeon design team hit the mark along with OP engineers to design a system that will help many kids in the years to come”.
About OrthoPediatrics Corp.
Founded in 2006, OrthoPediatrics is an orthopedic company focused exclusively on advancing the field of pediatric orthopedics. As such it has developed the most comprehensive product offering to the pediatric orthopedic market to improve the lives of children with orthopedic conditions. OrthoPediatrics currently markets 52 systems that serve three of the largest categories within the pediatric orthopedic market. This product offering spans trauma and deformity, scoliosis, and sports medicine/other procedures. OrthoPediatrics’ global sales organization is focused exclusively on pediatric orthopedics and distributes its products in the United States and over 70 countries outside the United States. For more information, please visit www.orthopediatrics.com.
Investor Contact
Philip Trip Taylor
Gilmartin Group
This email address is being protected from spambots. You need JavaScript enabled to view it.
415-937-5406
Last Trade: | US$22.81 |
Daily Change: | -0.12 -0.52 |
Daily Volume: | 145,759 |
Market Cap: | US$552.230M |
November 06, 2024 August 05, 2024 August 05, 2024 May 06, 2024 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB